ondansetron has been researched along with Cancer of Ovary in 24 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 9.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 9.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 9.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 6.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 5.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "The addition of bromazepam to ondansetron, and the extension of antiemetic prophylaxis to the day before and the day after chemotherapy improves the control of nausea and emesis compared to ondansetron monotherapy in patients with ovarian cancer." | 5.08 | Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. ( Conrad, A; Kuhn, W; Meden, H; Meissner, O, 1996) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 5.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| "Ondansetron, a selective 5-HT3 receptor antagonist, has already been reported to have a marked effect to alleviate or prevent nausea and vomiting associated with cancer chemotherapy, after its intravenous administration." | 5.07 | [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Patients who had suffered severe vomiting on carboplatin alone (23 patients with ovarian carcinoma) or in combination (two patients with testicular cancer) despite intensive antiemetic regimens were treated with ondansetron, given as 8 mg immediately prior to carboplatin followed by 8 mg orally, 8 hourly for 5 days." | 5.07 | Reduction of carboplatin induced emesis by ondansetron. ( Dickson, DS; Evans, BD; Harvey, VJ; Langley, GB; Mak, D; Mitchell, PL; Neave, LM, 1991) |
| "The efficacy and safety of ondansetron has led to the widespread use of this medication in the treatment of nausea and vomiting caused by cancer chemotherapy and radiation therapy." | 3.69 | Anaphylactoid reactions associated with ondansetron. ( Kossey, JL; Kwok, KK, 1994) |
| "We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course." | 2.68 | Impact of tumour burden on chemotherapy-induced nausea and vomiting. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | 2.68 | Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Emesis is one of the most disturbing side-effects of platinum therapy." | 2.67 | Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. ( du Bois, A; Karck, U; Madjar, H; Meerpohl, HG; Prömpeler, H; Thomssen, C; Vach, W, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Ondansetron was given as 4 mg oral +4 mg iv 30 minutes prior to carboplatin followed by 8 mg oral tds for 5 days." | 2.67 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group. ( Howells, N; Lambert, HE; McQuade, B; Rustin, GJ; Smith, DB, 1991) |
| "Palonosetron was always administered as a single-day therapy while one- or multi-day ondansetron therapy was administered in 27% and 73% of cycles, respectively." | 1.37 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. ( Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC, 2011) |
| "Survival of patients with advanced gastric cancer with Krukenberg's tumor is poor." | 1.32 | [A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum]. ( Akiba, Y; Aoki, D; Hibi, T; Ishii, H; Kato, S; Mukai, M; Naito, K; Takada, Y; Watanabe, C, 2003) |
| " The dosage protocols with which it has usually been employed establish an i." | 1.29 | Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer. ( Cagnazzo, G; Marinaccio, M; Miniello, G; Pinto, V, 1993) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (79.17) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, YC | 1 |
| McDonnell, A | 1 |
| Klinger, E | 1 |
| Fowler, B | 1 |
| Matta, L | 1 |
| Voit, D | 1 |
| Reddy, P | 1 |
| Akiba, Y | 1 |
| Watanabe, C | 1 |
| Takada, Y | 1 |
| Naito, K | 1 |
| Aoki, D | 1 |
| Mukai, M | 1 |
| Kato, S | 1 |
| Hibi, T | 1 |
| Ishii, H | 1 |
| Kossey, JL | 1 |
| Kwok, KK | 1 |
| du Bois, A | 2 |
| Vach, W | 1 |
| Thomssen, C | 1 |
| Karck, U | 1 |
| Madjar, H | 1 |
| Prömpeler, H | 1 |
| Meerpohl, HG | 2 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Hursti, TJ | 3 |
| Fredrikson, M | 4 |
| Steineck, G | 4 |
| Börjeson, S | 3 |
| Fürst, CJ | 4 |
| Peterson, C | 4 |
| Pinto, V | 1 |
| Marinaccio, M | 1 |
| Miniello, G | 1 |
| Cagnazzo, G | 1 |
| Goddard, M | 1 |
| Meden, H | 1 |
| Meissner, O | 1 |
| Conrad, A | 1 |
| Kuhn, W | 1 |
| Avall-Lundqvist, E | 2 |
| Morimoto, Y | 1 |
| Nakamura, M | 1 |
| Tamura, T | 1 |
| Kunii, T | 1 |
| Shimizu, K | 1 |
| Miyauchi, Y | 1 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Cannata, G | 1 |
| Gebbia, N | 1 |
| Lomberg, H | 1 |
| Sawaguchi, K | 1 |
| Yabushita, H | 1 |
| Tsukada, H | 1 |
| Yamada, H | 1 |
| Noguchi, M | 1 |
| Nakanishi, M | 1 |
| Morrow, GR | 1 |
| Hickok, JT | 1 |
| DuBeshter, B | 1 |
| Lipshultz, SE | 1 |
| Weiss, KS | 1 |
| Manusirivithaya, S | 1 |
| Chareoniam, V | 1 |
| Isariyodom, P | 1 |
| Sungsab, D | 1 |
| Furue, H | 2 |
| Ikeda, M | 2 |
| Tsukagoshi, S | 2 |
| Taguchi, T | 2 |
| Fujii, T | 1 |
| Rikimaru, T | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Niitani, H | 1 |
| Akasaka, Y | 1 |
| Ohta, J | 1 |
| Suminaga, M | 1 |
| Harvey, VJ | 1 |
| Evans, BD | 1 |
| Mitchell, PL | 1 |
| Mak, D | 1 |
| Neave, LM | 1 |
| Langley, GB | 1 |
| Dickson, DS | 1 |
| Johansson, S | 1 |
| Hursti, T | 1 |
| Smith, DB | 1 |
| Rustin, GJ | 1 |
| Howells, N | 1 |
| Lambert, HE | 1 |
| McQuade, B | 1 |
| Wilhelm, C | 1 |
| Quaas, L | 1 |
| Barnickel, I | 1 |
| Pfleiderer, A | 1 |
17 trials available for ondansetron and Cancer of Ovary
| Article | Year |
|---|---|
Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Female; Hu | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenh | 1994 |
Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; | 1993 |
Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bromazepam; Cisplatin; Cyclophosphamide | 1996 |
Impact of tumour burden on chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; C | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; | 1996 |
[Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cross-Over Studies | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chi-Square Distribution; Cisplatin; Dexamethasone; | 2001 |
[Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 2002 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
Reduction of carboplatin induced emesis by ondansetron.
Topics: Antiemetics; Carboplatin; Dysgerminoma; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondan | 1991 |
Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biperiden; Cisplatin; Dexa | 1991 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group.
Topics: Adult; Aged; Carboplatin; Epithelium; Female; Humans; Imidazoles; Middle Aged; Nausea; Ondansetron; | 1991 |
[Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response R | 1990 |
7 other studies available for ondansetron and Cancer of Ovary
| Article | Year |
|---|---|
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administra | 2011 |
[A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; | 2003 |
Anaphylactoid reactions associated with ondansetron.
Topics: Adult; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cis | 1994 |
Simplified ondansetron regimens for antiemetic prophylaxis in cisplatin-based chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Protocols; Female; Humans; Nause | 1993 |
The real costs of emesis.
Topics: Antiemetics; Carboplatin; Cisplatin; Drug Costs; Female; Humans; Metoclopramide; Ondansetron; Ovaria | 1993 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Anaphylactic reaction to ondansetron.
Topics: Anaphylaxis; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Age | 2001 |